Quarterly Financial Summary (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2014

Quarterly Financial Information Disclosure [Abstract]

Quarterly Financial Summary

	First Quarter			Second Quarter			Third Quarter			Fourth Quarter
	(In thousands, except per share amounts)
2014
Net sales	$	599,843		$	604,721		$	642,418		$	598,566
Gross profit	$	195,599		$	207,363		$	205,446		$	162,440
Restructuring and other charges, net(a)	$	17,000		$	3,332		$	293		$	5,322
Acquisition and integration related costs(b)	$	—		$	4,843		$	10,261		$	15,054
Net income (loss) from continuing operations	$	66,004		$	89,404		$	88,019		$	(12,990	)
Loss from discontinued operations (net of tax)(c)	(1,769		)	(60,025		)	(6,679		)	(1,058		)
Net income attributable to noncontrolling interests	(7,652		)	(6,932		)	(8,546		)	(4,460		)
Net income (loss) attributable to Albemarle Corporation	$	56,583		$	22,447		$	72,794		$	(18,508	)
Basic earnings (loss) per share:
Continuing operations	$	0.73		$	1.05		$	1.02		$	(0.22	)
Discontinued operations	(0.02		)	(0.76		)	(0.09		)	(0.02		)
	$	0.71		$	0.29		$	0.93		$	(0.24	)
Shares used to compute basic earnings per share	79,735			78,662			78,244			78,144
Diluted earnings (loss) per share:
Continuing operations	$	0.73		$	1.04		$	1.01		$	(0.22	)
Discontinued operations	(0.02		)	(0.76		)	(0.08		)	(0.02		)
	$	0.71		$	0.28		$	0.93		$	(0.24	)
Shares used to compute diluted earnings per share	80,112			79,091			78,659			78,545

	First Quarter			Second Quarter			Third Quarter			Fourth Quarter
	(In thousands, except per share amounts)
2013
Net sales	$	586,597		$	576,842		$	591,196		$	639,635
Gross profit	$	195,911		$	191,670		$	209,611		$	253,279
Restructuring and other charges, net(a)	$	—		$	—		$	—		$	33,361
Net income from continuing operations	$	87,681		$	88,500		$	97,313		$	162,232
Income (loss) from discontinued operations (net of tax)	1,835			2,628			531			(886		)
Net income attributable to noncontrolling interests	(5,529		)	(8,389		)	(7,332		)	(5,413		)
Net income attributable to Albemarle Corporation	$	83,987		$	82,739		$	90,512		$	155,933
Basic earnings (loss) per share:
Continuing operations	$	0.93		$	0.95		$	1.10		$	1.93
Discontinued operations	0.02			0.03			0.01			(0.01		)
	$	0.95		$	0.98		$	1.11		$	1.92
Shares used to compute basic earnings per share	88,719			84,028			81,385			81,226
Diluted earnings (loss) per share:
Continuing operations	$	0.92		$	0.95		$	1.10		$	1.92
Discontinued operations	0.02			0.03			0.01			(0.01		)
	$	0.94		$	0.98		$	1.11		$	1.91
Shares used to compute diluted earnings per share	89,236			84,489			81,852			81,713

(a) See Note 20, “Restructuring and Other.”

(b) See Note 23, “Acquisitions.”

(c) Included in Loss from discontinued operations (net of tax) for the year ended December 31, 2014 is $(65.7) million related to the loss on the sale of our antioxidant, ibuprofen and propofol businesses and assets, the majority of which was recorded in the second quarter. See Note 2, “Discontinued Operations.”